Immutep Ltd
ASX:IMM

Watchlist Manager
Immutep Ltd Logo
Immutep Ltd
ASX:IMM
Watchlist
Price: 0.305 AUD 7.02% Market Closed
Market Cap: 443.6m AUD
Have any thoughts about
Immutep Ltd?
Write Note

Intrinsic Value

IMM's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IMM stock under the Base Case scenario is 0.833 AUD. Compared to the current market price of 0.305 AUD, Immutep Ltd is Undervalued by 63%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IMM Intrinsic Value
0.833 AUD
Undervaluation 63%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Immutep Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IMM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IMM?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Immutep Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Immutep Ltd

Provide an overview of the primary business activities
of Immutep Ltd.

What unique competitive advantages
does Immutep Ltd hold over its rivals?

What risks and challenges
does Immutep Ltd face in the near future?

Has there been any significant insider trading activity
in Immutep Ltd recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Immutep Ltd.

Provide P/S
for Immutep Ltd.

Provide P/E
for Immutep Ltd.

Provide P/OCF
for Immutep Ltd.

Provide P/FCFE
for Immutep Ltd.

Provide P/B
for Immutep Ltd.

Provide EV/S
for Immutep Ltd.

Provide EV/GP
for Immutep Ltd.

Provide EV/EBITDA
for Immutep Ltd.

Provide EV/EBIT
for Immutep Ltd.

Provide EV/OCF
for Immutep Ltd.

Provide EV/FCFF
for Immutep Ltd.

Provide EV/IC
for Immutep Ltd.

Show me price targets
for Immutep Ltd made by professional analysts.

What are the Revenue projections
for Immutep Ltd?

How accurate were the past Revenue estimates
for Immutep Ltd?

What are the Net Income projections
for Immutep Ltd?

How accurate were the past Net Income estimates
for Immutep Ltd?

What are the EPS projections
for Immutep Ltd?

How accurate were the past EPS estimates
for Immutep Ltd?

What are the EBIT projections
for Immutep Ltd?

How accurate were the past EBIT estimates
for Immutep Ltd?

Compare the revenue forecasts
for Immutep Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Immutep Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Immutep Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Immutep Ltd compared to its peers.

Compare the P/E ratios
of Immutep Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Immutep Ltd with its peers.

Analyze the financial leverage
of Immutep Ltd compared to its main competitors.

Show all profitability ratios
for Immutep Ltd.

Provide ROE
for Immutep Ltd.

Provide ROA
for Immutep Ltd.

Provide ROIC
for Immutep Ltd.

Provide ROCE
for Immutep Ltd.

Provide Gross Margin
for Immutep Ltd.

Provide Operating Margin
for Immutep Ltd.

Provide Net Margin
for Immutep Ltd.

Provide FCF Margin
for Immutep Ltd.

Show all solvency ratios
for Immutep Ltd.

Provide D/E Ratio
for Immutep Ltd.

Provide D/A Ratio
for Immutep Ltd.

Provide Interest Coverage Ratio
for Immutep Ltd.

Provide Altman Z-Score Ratio
for Immutep Ltd.

Provide Quick Ratio
for Immutep Ltd.

Provide Current Ratio
for Immutep Ltd.

Provide Cash Ratio
for Immutep Ltd.

What is the historical Revenue growth
over the last 5 years for Immutep Ltd?

What is the historical Net Income growth
over the last 5 years for Immutep Ltd?

What is the current Free Cash Flow
of Immutep Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Immutep Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Immutep Ltd

Current Assets 191.4m
Cash & Short-Term Investments 181.9m
Receivables 7.6m
Other Current Assets 1.9m
Non-Current Assets 10.2m
PP&E 679.7k
Intangibles 8.2m
Other Non-Current Assets 1.3m
Current Liabilities 10.5m
Accounts Payable 3.8m
Accrued Liabilities 690.6k
Other Current Liabilities 6m
Non-Current Liabilities 1.6m
Long-Term Debt 1.4m
Other Non-Current Liabilities 211k
Efficiency

Earnings Waterfall
Immutep Ltd

Revenue
119.6k AUD
Operating Expenses
-50.5m AUD
Operating Income
-50.4m AUD
Other Expenses
7.7m AUD
Net Income
-42.7m AUD

Free Cash Flow Analysis
Immutep Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IMM Profitability Score
Profitability Due Diligence

Immutep Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROE is Increasing
Negative 1-Year Revenue Growth
Declining ROIC
17/100
Profitability
Score

Immutep Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

IMM Solvency Score
Solvency Due Diligence

Immutep Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Immutep Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMM Price Targets Summary
Immutep Ltd

Wall Street analysts forecast IMM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMM is 0.969 AUD with a low forecast of 0.707 AUD and a high forecast of 1.155 AUD.

Lowest
Price Target
0.707 AUD
132% Upside
Average
Price Target
0.969 AUD
218% Upside
Highest
Price Target
1.155 AUD
279% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IMM?

Click here to dive deeper.

Dividends

Immutep Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for IMM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IMM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Immutep Ltd Logo
Immutep Ltd

Country

Australia

Industry

Biotechnology

Market Cap

447.2m AUD

Dividend Yield

0%

Description

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

Contact

NEW SOUTH WALES
Sydney
Plaza Building, L 12 95 Pitt St
+61292761224.0
www.immutep.com

IPO

1988-06-23

Employees

-

Officers

CEO, MD, CFO, Chief Business Officer & Executive Director
Mr. Marc Voigt
COO, General Counsel & Joint Company Secretary
Ms. Deanne Miller LLB
Chief Scientific Officer & Executive Director
Dr. Frederic Triebel M.D., Ph.D.
Chief Medical Officer
Dr. Florian D. Vogl M.D., M.Sc., Ph.D.
Senior Vice President of Regulatory & Strategy
Mr. Christian Mueller BBA, MSc.
Joint Company Secretary
Ms. Indira Naidu

See Also

Discover More
What is the Intrinsic Value of one IMM stock?

The intrinsic value of one IMM stock under the Base Case scenario is 0.833 AUD.

Is IMM stock undervalued or overvalued?

Compared to the current market price of 0.305 AUD, Immutep Ltd is Undervalued by 63%.

Back to Top